New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders
Year: 2015
Type: review
Abstract: The applicability of stable gut hormones for the treatment of obesity-related diabetes is now undisputable. This is based predominantly on prominent and sustained glucose-lowering actions, plus evidence that these peptides can augment insulin secretion and pancreatic islet function over time. This review highlights the therapeutic potential of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), oxyntomodulin (OXM) and cholecystokinin (CCK) for obesity-related diabetes. Stable GLP-1 mimetics have already been successfully adopted into the diabetic clinic, whereas GIP, CCK and OXM molecules offer promise as potential new classes of antidiabetic drugs. Moreover, recent studies have shown improved therapeutic effects following simultaneous modulation of multiple receptor signalling pathways by combination therapy or use of dual/triple agonist peptides. However, timing and composition of injections may be important to permit interludes of beta-cell rest. The review also addresses the possible perils of incretin based drugs for treatment of prediabetes. Finally, the unanticipated utility of stable gut peptides as effective treatments for complications of diabetes, bone disorders, cognitive impairment and cardiovascular dysfunction is considered.
Source: World Journal of Diabetes
Authors: Nigel Irwin, Peter R Flatt
Institution: University of Ulster
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: incretins, obesity-related diabetes, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, oxyntomodulin, cholecystokinin, GLP-1 receptor agonists, GIP receptor agonist, combination therapy, dual agonist, prediabetes, diabetes complications, bone disease, cognitive impairment, cardiovascular dysfunction
Open Access status: diamond
OpenAlex ID: W2178160651
